Market Overview

Immune Biosolutions Enters into a Research Collaboration and License Agreement with Johnson & Johnson Innovation to Identify and Develop Therapeutic Antibodies for Multiple Targets

Share:

Immune Biosolutions Inc. (IBio), a JLABS @ Toronto resident company,
today announced a research collaboration and license agreement with
Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of
Johnson & Johnson. The agreement, facilitated by Johnson & Johnson
Innovation LLC, will focus initially on the discovery and development of
therapeutic antibodies in oncology.

The collaboration will utilize IBio's proprietary Nebula antibody
discovery platform to advance oncology targets that historically have
been a challenge for therapeutic development. "IBio's Nebula platform
provides a new angle to antibody discovery with four families of
technologies integrated within a single platform to deliver innovative
antibody therapies in key disease areas. We are excited to be working
with Janssen in this promising new area which we believe has the
potential to transform and improve human health," said Frédéric Leduc,
chief executive officer of Immune Biosolutions.

Financial terms of the agreement are not being disclosed.

About Immune Biosolutions Inc.

Immune Biosolutions (IBio) is an innovative biotech company specialized
in the discovery and engineering of chicken humanized antibodies that
target proteins with a recognized, yet unexploited, therapeutic
potential. Through its Nebula Antibody Platform, Immune Biosolutions
generates high-value recombinant antibody portfolios against
historically difficult targets.

For more information: www.immunebiosolutions.com

View Comments and Join the Discussion!